EUVIMEDEUVIMED entdecken
Crossref

The FDA and Gene Therapy for Duchenne Muscular Dystrophy

David M Rind

JAMA · 2024

DOI: 10.1001/jama.2024.5613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von David M Rind. Beteiligte Einrichtung: Institute for Clinical and Economic Review, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Genetic Therapy, Muscular Dystrophy, Duchenne, United States Food and Drug Administration. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with surrogate outcomes that did not demonstrate net benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyMuscular Dystrophy, DuchenneUnited States Food and Drug AdministrationHumansDrug ApprovalDystrophinUnited StatesMaleChild, PreschoolChildClinical Trials as Topic

Substanzen

DystrophinDMD protein, human

Autor:innen und Institutionen

  • Institute for Clinical and Economic Review, Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Rind, D. M. (2024). The FDA and Gene Therapy for Duchenne Muscular Dystrophy. JAMA. https://doi.org/10.1001/jama.2024.5613

Vancouver

Rind DM. The FDA and Gene Therapy for Duchenne Muscular Dystrophy. JAMA. 2024. doi:10.1001/jama.2024.5613

BibTeX
@article{Rind2024,
  author = {Rind, David M},
  title = {The FDA and Gene Therapy for Duchenne Muscular Dystrophy},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.5613}
}
Kostenlos starten →